Linda Tannenbaum is Founder and CEO/President of Open Medicine Foundation (OMF), an independent non-profit dedicated to funding and facilitating open and collaborative scientific research towards clinical breakthroughs for chronic complex diseases, such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Ms. Tannenbaum founded OMF after her daughter came down with sudden onset ME/CFS. Realizing that open, global collaborative research into the disease was lacking, she established OMF to facilitate large-scale research to find a cure for these chronic complex diseases.
An accomplished speaker, Ms. Tannenbaum has spoken and keynoted worldwide. Her presentations have drawn enthusiastic responses from scientists as well as clinicians and patients because of her ability to simplify complex science and also, because of her passionate empathy for patients and their caretakers. Ms. Tannenbaum has a background in science with a bachelor’s in bacteriology from UCLA and a clinical laboratory scientist license.
As a Partner and Co-Founder of KMT Partners, and CEO of Enterprise Rebirth Advisory, Ms. Hicks provides consulting and advisory services to boards, investors, and management teams on building value and sustainability for profit and non-profit organizations and is currently focused on projects in the healthcare industry. Having recently served as Chief Administrative Officer of the International Securities Exchange, Ms. Hicks is a finance industry veteran with over 20 years of leadership experience across both private and public sectors and global merger integration experience. Ms. Hicks also recently served as the Chair- Elect of the Boys Town NY Board of Directors.
As a patient, Ms. Hicks is personally focused on solving the big questions of the causes and treatments for ME/CFS and other complex disorders and ensuring patient engagement is central to those solutions.
Ms. Hicks holds an MA in Industrial/Organizational Psych
Ms. Linsley is a senior vice president of Crescent Capital Group LP. She is responsible for directing Crescent’s charitable giving activities. She is also responsible for coordinating Crescent’s annual Partners Conference. Before taking this role in the company, she managed the Human Resources department for 24 years.
Prior to joining the Crescent team, Ms. Linsley worked in the International Capital Markets Group and High Yield Bond Department of Drexel Burnham Lambert, Inc. Ms. Linsley studied Business Administration at Mesa College in California.
Joseph Morin is Co-Founder / CEO Social Rewards – a Social Media based marketing platform. Prior to founding Social Rewards, Joseph served as Vice President of Search and Social Marketing for Fly.com (a Travelzoo (NASDAQ:TZOO) company) and also served as Vice President of Strategic Marketing for UsedCars.com where as a Principal, he was instrumental in the sale of the company to Cobalt Automotive Group. Previously he was Strategic Marketing Director for Autobytel, Inc., (NASDAQ: ABTL) the nation’s largest online new car buying service for a two-year period and pioneered their search marketing program.
As a consultant over the last decade with Boost Search Marketing Joseph has worked with many companies on online marketing strategies including Austin Ventures, Autobytel, Inc., Azure Capital, Business.com, Clearstone Venture Capital, CreditCards.com, Dentist.net, Education.com, Enterprise Rent-A-Car, Fly.com, Klout.com, Microsoft, MGM Resorts, MRM Worldwide (div. of Interpublic Group of Cos), Planet Hollywood Resort & Casino, Travelzoo, Tribune Interactive, UsedCars.com and World Publications. He currently sits on the Advisory Board of Klout.
Joseph is a featured speaker at Internet Marketing conferences around the world having spoken at conferences such as Pubcon, Search Engine Strategies (now ClickZ), and SMX in New York, Chicago, Los Angeles, Miami, Seattle, Las Vegas, San Jose, Toronto, Stockholm, London, Tokyo and Sao Paulo and is an organizer for the PubCon series of Internet Marketing conferences.
R.P. Channing Rodgers is currently a professor at UCSF with a focus on informatics research and training.
Previously, he was a clinical officer at the FDA in the office of Orphan Product Development, where he leveraged informatics to identify overlooked therapies for rare diseases, created a network-based course for small clinical trials, and reviewed grant and orphan drug applications.
Dr. Rodgers joined the FDA from the NIH, where he had the distinction of being the first physician to actively develop biomedical applications for the Web. At the NIH, he was the founding chair of the National Science Foundation’s Web Consortium, and he co-created the first large catalogued image archive for the Web and devised and directed an Internet-based multimedia course: “The Science of Small Clinical Trials.”
Dr. Rodgers received training at Harvard College and the University of Utah College of Medicine. He received postdoctoral training at the University of London, NCI’s Laboratory of Theoretical Biology, and the International Institute of Cellular and Molecular Pathology (Brussels). He completed training in Clinical Pathology within the Department of Laboratory Medicine in the School of Medicine at the University of California, San Francisco. Dr. Rodgers has published extensively and was formerly the editor-in-chief of the journal Computers in Biology and Medicine.
Dr. Rose is a psychiatrist in private practice in Palo Alto, California. She has over 40 years of experience in treating posttraumatic stress disorder, both acute PTSD and complex PTSD. She has developed and published a model for psychodynamic psychotherapy of PTSD and has published articles and book chapters on these subjects. She has taught extensively for professionals and for the lay public and has consulted to the National Centers for PTSD.
Dr. Rose’s interest in serving on our board stems from both her personal experience of having fibromyalgia and then ME/CFS, and also from having patients in her practice with these illnesses. She is very excited about the pending revolutionary research and about current interventions that have brought her and her patients notable relief.
Hany Zayed, Ph.D. is the head of Data Science Solutions group at Rigel Pharmaceuticals. He has more than 25 years of experience in development of novel treatments. He has special research interest in the development of novel treatments and therapeutics of rare and orphan indications. Prior to joining Rigel, he was the Head of Biometrics at AbbVie Stemcentrx, XOMA and Nektar Therapeutics where he played vital roles in the development and regulatory approval of novel treatments in various therapeutic areas including oncology, hematology and immunology to US and European patients. He received a Ph.D. in Biostatistics in 2001.